HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)
NCT03685708
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
78
Enrollment
NIH
Sponsor class
Conditions
Hepatitis
Safety and Tolerability
Interventions
BIOLOGICAL:
HEPLISAV-B
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)